- costs $100 @ scale vs. $150K for legacy
- its cold cathode tech greatly reduces heat damage & extends lifetime
- 70-90% smaller vs. legacy tube -- reduces weight & enables multi-source units for 3D imaging (broader applications vs. legacy X-ray)
$NNOX value prop (2/4) -- better imaging
Multiple X-ray sources (up to 11) allows for
- more angles
- more tests
Digital approach enables
- clearer imaging
- less unnecessary radiation exposure -- comparatively limited Ma & KvP
(ARC image on the left)
Quick note on buzzwords:
- Ma = brightness
- KvP = speed of electron emission
- both are positively correlated w/radiation exposure
- specifically: KvP of 40 & Ma of 1.5 for $NNOX vs. typical levels of 50-60 & 3-5 respectively
$NNOX value prop (3/4) -- broader access
All in cost of $15k/unit enables pay/scan model.
Units distributed for free.
W/radiology not affordable to 2/3 of 🌎 this is big.
$NNOX's software/AI partners enable assistance w/diagnosis, remote care, organizing patient history etc.
Value prop (4/4) -- optionality
Source uses per $NNOX
- X-ray
- Fluoroscopy
- Angiography
- Mammography
- Veterinary
- Security
- Manufacturing (Quality control per SK)
& (pending multi-source clearance) uses in
- CT
- Some MRI test mimicking
Need single source clearance 1st!
How does it work? (1/2)
X-ray source powered by silicon semiconductor (chip)
- full name: digital microelectromechanical system chip cold-cathode -- MEMs chip
- 100M Molybdenum nano-cones capable of digital & precise electron emission
- more control, rapid switching, less waste
How does it work? (2/2)
The $NNOX source replaces thermionic filament need in traditional tubes used to emit electrons.
What the heck does this mean?
No need for extreme heat & subsequent cooling so again:
- less power
- more durable
- far smaller & cheaper machine 👍
Digital X-Ray Competition (1/2)
Several other digital cold-cathode companies in the industry.
All use carbon nano tube (CNT) base for X-ray sources while Nanox uses the MEMs base we touched on.
How do these two methods compare? 👇👇
Digital X-Ray Competition (2/2) -- CNT vs. MEMs
CNT is
- less stable
- prone to heat damage (less durable)
No viable, long-term commercial solution among CNT comp after “significant investment.”
$NNOX Molybdenum-cones proven more suitable for scale vs. carbon-tubes.
FDA clearance approach
Aims for single-source clearance 1st (proof of concept).
Then multi-source (more dynamic).
Will soon resubmit single source app.
Will resubmit multi-source app in 2021.
Hopes to deploy 1000 units Q1 2022 & 15K by 2025.
speaking of clearance...
🐘 in the room (1/2)
Last year, $NNOX received a deficiency letter on its single source app.
Last week it filed a 6k informing investors of another deficiency letter.
Issues included needing:
- more support for Arc uses
- more comparability of Arc to legacy devices
🐘 in the room (2/2)
No clearance severely diminishes the IP's value.
Would then be for non-medical uses only.
‼️ I used 2nd letter as a cue to take profit on 44% of my position. $NNOX is now 1.5% of my holdings.‼️
Regardless of mgmt's confidence, no guarantee it's cleared.
Scale approach (1/2) -- Distribution
- building 100 units for a dry run
- first to urgent care centers, private clinic chains, outpatient clinics, “retail locations” before attempting to disrupt hospital system
Scale approach (2/2) -- Open source
- $NNOX will not be aiming to displace $GE or other radiology incumbents
- tube/source IP available to anyone for licensing fees
- philosophy: sharing is caring... & lucrative 🙂
Leadership hints at where these licensing deals could occur 👇
Leadership (1/4) -- Advisory board
Morry Blumenfeld
- $GE higher-up in medical systems
$SKM
- 2 investments in $NNOX for $25M
- Nanox-related hires for chips/AI/Cloud
- will place 2.5K units if cleared
- partner on new Korean subsidiary/factory
$FUJIY
- invested
- mammography OEM customer
Foxconn
- invested
- main manufacturing partner
Math if cleared (1/2)
$NNOX expects:
- to charge $40/scan
- to collect $14/scan in revenue after partners paid
- revenue to be in “mostly profit”
Math if cleared (2/2)
Current contracts & collaborations =
- 10,650 units
- MIN 7 scans/day/unit based on contracts
Current deals = MIN $380M in revs
Expect closer to 20 scans/day/unit = $1.09B in revs
Global average for scans/X-ray unit/day is 60.
20 is pessimistic.
More math
Assuming
- most pessimistic scan/day outcome
- most pessimistic take-away from Ran’s reiterated “mostly in profits” comments (so 50% profit)
- unit cost of $15K
We get a:
- 306 day profit payback period/unit.
- 153 day revenue payback period/unit.
Promising future (only if cleared)
“In negotiations with”
- India
- Canada
- The UK
& many more
Also have not begun licensing deals.
“Flood of interest” in $NNOX's arc machine post RSNA according to Ran.
- Revs down 23% YOY to $1.03B -- misses by 4%
-- "trended ahead of forecast pre pandemic-related closures"
- 35.5% EBITDA margin -- +570 bps YOY
- $13M in net income vs. -$93M YOY
- 11.6% op margin +1060 bps YOY
- $577M in net debt vs. $1.9B YOY
- Growing Pennsylvania share (see image)
- Excelling in Michigan -- 48K users in 10 days (see other image)
- Will be live in 10+ states in 2021
- 15% of Mich users convert to $PENN loyalty program already
& again.. 0 external marketing spend.
$PENN Q4 -- Barstool omni-channel impact
In the week following Barstool re-brand at its East Chicago Property:
- +35% betting handle
- +27% table volume
- +26% slots volume
“CURI is John Hendrick’s original vision of Discovery… before its shift to reality TV"
- CURI capitalizes on the void a shift to reality creates
- "we want to be a trusted home resource"
$CURI's Needham call -- CEO Stinchcomb
Why competition is moving to reality?
- appeals to 80% of consumers
- factual just 60%
BUT -- $CURI seeks corporate parters SO
- brand quality imperative
- content focus a must
& views factual content as
- longer shelf life
- higher LTV
$CURI's Needham call -- CEO Stinchcomb
Ad plans:
- no plans to incorporate 30-60 second commercials
- open to more subtle ad forms for "strictly blue-chip clients"
- considered sponsorships not ads
- competitors' shift to SVOD makes $CURI's sponsorships more & more valuable
"Transforming the Russian consumer economy by offering the widest selection, best value & maximum online shopping convenience while empowering sellers to achieve greater commercial success."
The value proposition:
a. For active buyers
--Widest multi-category selection
--"Exceptional value & convenience"
b. For active sellers
--Access to larger audience
--Ozon fulfillment
--"Advanced analytics tools"
--Lending options 👀
--ad & data services